Press Releases Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2024 BST			5-day change	1st Jan Change
4.51 ^USD	+0.45%		-3.84%	+70.19%

05-08	Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-07	Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones	05-08	GL
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference	05-07	GL
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results	03-19	GL
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update	03-12	GL
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024	11-13	GL
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	10/10/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	29/09/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	22/09/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	14/09/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	06/09/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	28/08/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	19/08/23	PR
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results	14/08/23	GL
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia	14/08/23	GL
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference	31/05/23	GL
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference	31/05/23	AQ
DESIGN THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)	09/05/23	AQ
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results	09/05/23	GL
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023	24/04/23	GL
DESIGN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	14/03/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Press Releases

Filters